Higher CD4 + T cell counts associated with low viral pol replication capacity among treatment-naive adulte in early HIV-1 infection

Journal of Infectious Diseases

Volumn 190, Issue 2, 2004, Pages 251-256

  Barbour, Jason D ^a,d,e   Hecht, Frederick M ^b,c   Wrin, Terri ^g   Segal, Mark R ^d,e   Ramstead, Clarissa A ^b,c   Liegler, Teri J ^a   Busch, Michael P ^b,c,f   Petropoulos, Christos J ^g   Hellmann, Nicholas S ^g   Kahn, James O ^b,c   Grant, Robert M ^a,b,c  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d Ctr Bioinfo and Molec Biostatist   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Blood Centers of the Pacific   (United States)

^g MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEINASE; VIRUS RNA; VIRUS VECTOR;

ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE DISTRIBUTION; VIRUS REPLICATION; VIRUS VIRULENCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; VIRULENCE; VIRUS REPLICATION;

EID: 3142678466     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422036     Document Type: Article

References (23)

1. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
2. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16:201-7.
3. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76:11104-12.
4. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-80.
5. + cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995; 333:1662-9.
6. Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999; 180:659-65.
7. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-8.
8. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-8.
9. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-11.
10. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-8.
11. Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr 2003; 33:625-34.
12. Grant RM, Kuritzkes DR, Johnson VA, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003; 41:1586-93.
13. Kuritzkes DR, Grant RM, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol 2003; 41:1594-9.
14. Diggle P, Liang K, Zeger S. Analysis of longitudinal data. Oxford: Oxford University Press, 1994.
15. Littell R, Milliken G, Stroup G. SAS system for mixed models. Cary, NC: SAS Institute, 1996.
16. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
17. Stoddart CA, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001; 7: 712-8.
18. Liegler TJ, Hayden MS, Lee KH, Hoh R, Deeks SG, Grant RM. Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. AIDS 2001; 15:179-84.
19. Penn ML, Myers M, Eckstein DA, et al. Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses 2001; 17:517-23.
20. Deeks SG, Grant RM, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003; 17:361-70.
21. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-43.
22. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7.
23. Barbour JD, Wrin T, Hecht FM, et al. Wide variation in pro/pol replication capacity in recently transmitted HIV-1 is conferred in part by protease inhibitor resistance mutations. Antivir Ther 2003; S80.